Intercept’s CRL Just Continues Upheaval In NASH
Executive Summary
With approval timeline for OCA now thoroughly unclear and Genfit on the ropes, might the top spot in NASH end up with Galmed, AbbVie, Madrigal, Inventiva or Gilead instead?
You may also be interested in...
Imminent Madrigal, Viking Trial Readouts Will Shape NASH R&D Expectations
While neither company reported new data from their ongoing trials at AASLD, the firm’s competing THRβ agonists are viewed as leading lights in the non-alcoholic steatohepatitis competition.
Will Intercept’s New NASH Analysis Pass FDA’s Muster?
The new analysis of REGENERATE, based on an FDA-requested methodology, shows continued efficacy for OCA, but analysts were circumspect about whether the benefit/risk profile would sway the agency.
Phase III Data In Suspected NASH Boost Madrigal’s Profile, But Bigger Data To Come
Resmetirom, Madrigal’s THRβ agonist, demonstrates safety and tolerability, and succeeds on secondary efficacy endpoints in a study serving as a precursor to the firm’s pivotal Phase III trial.